Literature DB >> 29746920

Animal models of NAFLD from the pathologist's point of view.

Helmut Denk1, Peter M Abuja2, Kurt Zatloukal2.   

Abstract

Fatty liver disease is a multifactorial world-wide health problem resulting from a complex interplay between liver, adipose tissue and intestine and initiated by alcohol abuse, overeating, various types of intoxication, adverse drug reactions and genetic or acquired metabolic defects. Depending on etiology fatty liver disease is commonly categorized as alcoholic or non-alcoholic. Both types may progress from simple steatosis to the necro-inflammatory lesion of alcoholic (ASH) and non-alcoholic steatohepatitis (NASH), respectively, and finally to cirrhosis and hepatocellular carcinoma. Animal models are helpful to clarify aspects of pathogenesis and progression. Generally, they are classified as nutritional (dietary), toxin-induced and genetic, respectively, or represent a combination of these factors. Numerous reviews are dealing with NASH animal models designed to imitate as closely as possible the metabolic situation associated with human disease. This review focuses on currently used mouse models of NASH with particular emphasis on liver morphology. Despite metabolic similarities most models (except those with chemically or genetically induced porphyria or keratin 18-deficiency) fail to develop the morphologic key features of NASH, namely hepatocyte ballooning and formation of histologically and immunohistochemically well-defined Mallory-Denk-Bodies (MDBs). Although MDBs are not universally detectable in ballooned hepatocytes in NASH their experimental reproduction and analysis may, however, significantly contribute to our understanding of important pathogenic aspects of NASH despite the obvious differences in etiology.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal models; Hepatocyte ballooning; Mallory-Denk bodies; NASH; Pathology; Steatohepatitis

Mesh:

Year:  2018        PMID: 29746920     DOI: 10.1016/j.bbadis.2018.04.024

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  16 in total

1.  Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach.

Authors:  Usman Sabir; Hafiz Muhammad Irfan; Aman Ullah; Yusuf S Althobaiti; Mulazim Hussain Asim
Journal:  J Inflamm Res       Date:  2022-02-24

Review 2.  Characterization of diet based nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes.

Authors:  Ghaidafeh Akbari; Seyyed Ali Mard; Feryal Savari; Barat Barati; Maryam J Sameri
Journal:  Histol Histopathol       Date:  2022-04-27       Impact factor: 2.130

Review 3.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

4.  Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice.

Authors:  Huimei Lu; Caiyong Ye; Xing Feng; Jingmei Liu; Mantu Bhaumik; Bing Xia; Chen Liu; Zhiyuan Shen
Journal:  Am J Pathol       Date:  2020-03-20       Impact factor: 4.307

Review 5.  From the origin of NASH to the future of metabolic fatty liver disease.

Authors:  Andreas Geier; Dina Tiniakos; Helmut Denk; Michael Trauner
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

6.  PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease.

Authors:  Maria E Moreno-Fernandez; Daniel A Giles; Jarren R Oates; Calvin C Chan; Michelle S M A Damen; Jessica R Doll; Traci E Stankiewicz; Xiaoting Chen; Kashish Chetal; Rebekah Karns; Matthew T Weirauch; Lindsey Romick-Rosendale; Stavra A Xanthakos; Rachel Sheridan; Sara Szabo; Amy S Shah; Michael A Helmrath; Thomas H Inge; Hitesh Deshmukh; Nathan Salomonis; Senad Divanovic
Journal:  Cell Metab       Date:  2021-05-17       Impact factor: 31.373

Review 7.  Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease.

Authors:  Ines C M Simoes; Justyna Janikiewicz; Judith Bauer; Agnieszka Karkucinska-Wieckowska; Piotr Kalinowski; Agnieszka Dobrzyń; Andrzej Wolski; Maciej Pronicki; Krzysztof Zieniewicz; Paweł Dobrzyń; Marcin Krawczyk; Hans Zischka; Mariusz R Wieckowski; Yaiza Potes
Journal:  Nutrients       Date:  2019-11-24       Impact factor: 5.717

8.  Attenuation of the Hepatoprotective Effects of Ileal Apical Sodium Dependent Bile Acid Transporter (ASBT) Inhibition in Choline-Deficient L-Amino Acid-Defined (CDAA) Diet-Fed Mice.

Authors:  Anuradha Rao; Ivo P van de Peppel; Sanjeev Gumber; Saul J Karpen; Paul A Dawson
Journal:  Front Med (Lausanne)       Date:  2020-02-25

9.  Murine Genetic Background Overcomes Gut Microbiota Changes to Explain Metabolic Response to High-Fat Diet.

Authors:  Zahra Safari; Aurélia Bruneau; Magali Monnoye; Mahendra Mariadassou; Catherine Philippe; Kurt Zatloukal; Philippe Gérard
Journal:  Nutrients       Date:  2020-01-21       Impact factor: 6.706

Review 10.  Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview.

Authors:  Daphne Pinheiro; Isabelle Dias; Karina Ribeiro Silva; Ana Carolina Stumbo; Alessandra Thole; Erika Cortez; Lais de Carvalho; Ralf Weiskirchen; Simone Carvalho
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.